Natural product therapy for tuberculosis: Grifolin, isolated from the mushroom Albatrellus confluenes, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation , promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up regulation of its target gene, 18/October/2016, 7.32 am

Natural product therapy for KRAS-mutant lung cancer: Ginsenoside, one of the main components in American ginseng herb, decreases the expression of XPO1, increases the level of NFKBIA, inhibits NFKB transcriptional activity and suppresses the progression of KRAS-mutant lung cancer via up regulation of its target gene, 18/October/2016, 11. 25 am
October 18, 2016
Natural product Life-extension therapy: Fisetin, isolated from Strawberry, Mango, and Cucumber, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span , 18/October/2016, 11.06 pm
October 18, 2016
Show all

A study from the Max Plank Institute for Infection Biology, Berlin, Germany shows that “CXCL5-secreting pulmonary epithelial cells drive destructive neutrophilic inflammation in tuberculosis.” This study was published in the 10 February 2014 issue of the“Journal of Clinical Investigations” [One of the best research journals in clinical medicine with an impact factor of 12.575] by Prof. Stefan H.E. Kaufman MJ, Geraldine Nouailles, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product therapy for tuberculosis: Grifolin, isolated from the mushroom Albatrellus confluenes, increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation, promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up-regulation of its target gene


Prof. Stefan Kaufman’s research team has shown earlier that knockdown of CXCL5 in mice inhibits recruitment of polymorphonuclear leukocytes, decreases pulmonary inflammation and inhibits the progression of pulmonary tuberculosis.

Significance:

Given that: (1) nearly 2.5 billion people out of 7.4 billion total world population are infected with M. tuberculosis; (2) majority of population in Asian and African countries test positive in tuberculin tests; (3) molecular pathways involved and the mechanism of development of drug-resistant tuberculosis is far from understood; (3) treating drug-resistant tuberculosis is still a daunting task; (6) tuberculosis is the second-leading cause of death–first being the HIV–due to an infectious disease; (7) in 2010, out of the 88 lakhs patients test positive for TB, 14.5 lakhs patients died; (8) billions of dollars are being spent each year globally for the treatment of tuberculosis; and (9) most of the TB cases are registered in developing countries—that cannot afford high-cost required for the treatment of drug-resistant TB—compared to developed countries, there is an urgent need to find: (i) a way to inhibit drug-resistant tuberculosis; (ii) a cheaper alternative to the existing expensive drugs; and (iii) a side-effect-free-Natural product-based drug that prevents relapse/recurrence of drug-resistant TB.


Research Findings: 

Figure 1  Grifolin inhibits pulmonary tuberculosis via down-regulation of (Toll-like receptor-TLR) TLR-2 and Chemokine CXCL5 and up-regulation of phosphatase MKP-1

Figure 1  Grifolin inhibits pulmonary tuberculosis via down-regulation of (Toll-like receptor-TLR) TLR-2 and Chemokine CXCL5 and up-regulation of phosphatase MKP-1

Grifolin

This study suggests a natural product-based therapy for life-threatening tuberculosis. Grifolin, by increasing the expression of its target gene, it may: (1) inhibit TLR-2 expression; (2) increase the expression of phosphatase MKP-1; (3) suppress the expression of Chemokine CXCL5 (C-X-C Motif Chemokine Ligand 5); (4) inhibit the recruitment of polymorphonuclear leukocytes; (5) decrease lung inflammation/injury; (6) promote clearance of M.tuberculosis; and (7) inhibit the progression of pulmonary tuberculosis. Together, pharmacological formulations encompassing “Grifolin or its analogues” may be used to treat pulmonary tuberculosis.


Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org or http://newbioideas.com

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Citation: Boominathan, Natural product therapy for tuberculosis: Grifolin, isolated from the mushroom Albatrellus confluenes,  increases the expression of MKP-1, inhibits TLR2 signalling, secretion of Chemokine CXCL5, and recruitment of polymorphonuclear leukocytes (PMNs), decreases destructive pulmonary inflammation , promotes M. tuberculosis clearance and inhibits pulmonary tuberculosis via up regulation of its target gene, 18/October/2016, 7.32 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

# Research cooperation


Undisclosed information: How Grifolin: (1) increases the expression of MKP-1; (2) inhibits TLR-2 signaling; and (3) inhibits Chemokine CXCL5 expression

Amount: $500

satisfaction-guarantee

Results-guaranteed-if-not-refunded

Comments are closed.